Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity

NCT07505303 is registered in ClinicalTrials.gov with Eccogene as lead sponsor.

NCT NCT07505303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07505303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity
Lead sponsor
Eccogene
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 23, 2026
Completion date
October 15, 2026
Enrollment
151 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

adult obesity, weight management